An Observational Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer, Colon Cancer in the Adjuvant Setting, Advanced Gastric Cancer or Breast Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01664494|
Recruitment Status : Completed
First Posted : August 14, 2012
Results First Posted : May 2, 2016
Last Update Posted : May 2, 2016
|Condition or disease||Intervention/treatment|
|Breast Cancer, Colorectal Cancer, Gastric Cancer||Drug: Capecitabine|
|Study Type :||Observational|
|Actual Enrollment :||563 participants|
|Official Title:||A Non-Interventional Trial of Xeloda in Metastatic Colorectal Cancer, Adjuvant Colon Cancer, Advanced Gastric Cancer and Breast Cancer|
|Study Start Date :||April 2010|
|Actual Primary Completion Date :||July 2012|
|Actual Study Completion Date :||July 2012|
Participants will receive capecitabine according to the label text as monotherapy (1250 mg/m^2 twice daily) or combination therapy (800 to 1000 mg/m^2 or 1250 mg/m^2 twice daily) for 14 consecutive days followed by a treatment break of 7 days.
Capecitabine will be given according to the label text as monotherapy (1250 mg/m^2 twice daily) or combination therapy (800 to 1000 mg/m^2 or 1250 mg/m^2 twice daily) for 14 consecutive days followed by a treatment break of 7 days.
- Number of Participants With Routine Clinical Use of Capecitabine as Per the Line of Treatment [ Time Frame: Approximately 3 years; or up to disease progression, death or stop of capecitabine treatment, whichever occurred first ]Choice of line of treatment in adjuvant and advanced or metastatic cancer for capecitabine was observed.
- Median Dose of Capecitabine [ Time Frame: Approximately 3 years; or up to disease progression, death or stop of capecitabine treatment, whichever occurred first ]Median dose of capecitabine for treatment of metastatic colorectal cancer, adjuvant colon cancer, advanced gastric cancer, or metastatic breast cancer in this study was presented.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01664494
|Wien, Austria, 1090|
|Study Director:||Clinical Trials||Hoffmann-La Roche|